Trial Profile
A Continued Access Protocol for Eligible US Subjects With Duchenne Muscular Dystrophy Who Previously Participated in an Approved Drisapersen Study
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 01 Nov 2023
Price :
$35
*
At a glance
- Drugs Drisapersen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 24 Mar 2014 New trial record